2023-01-26 02:00:00

Genelux Corporation Announces Pricing of Initial Public Offering

Logo GlobeNewswire
GlobeNewswire

WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux or the Company), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/ordifficult-to-treatsolid tumor types, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.00 per share, for total gross proceeds of approximately $15.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Genelux. In addition, Genelux has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

In connection with the offering, the Companys shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol GNLX on January 26, 2023 subject to final approval by Nasdaq. The offering is expected to close on January 30, 2023, subject to satisfaction of customary closing conditions.

The Benchmark Company, LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as joint book-running managers for this offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on January 25, 2023. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, or by telephone at (212) 312-6700, or by email atprospectus@benchmarkcompany.com; or from Brookline Capital Markets, a division of Arcadia Securities, LLC, Attention: Michael Fontaine, 280 Park Avenue, Suite 43W, New York, NY 10017, or by telephone at (646) 256-5258, or by email at michael.fontaine@brooklinecapmkts.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genelux Corporation

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux's discovery and development efforts revolves around the Company's proprietary CHOICE platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements, including with respect to the proposed initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Genelux, including those set forth in the Risk Factors section of Geneluxs registration statement for the initial public offering filed with the SEC. Copies are available on the SECs website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Ankit Bhargava, MD
Allele Communications, LLC
815.721.4912
abhargava@allelecomms.com


Continue read on globenewswire.com

Logo PR Newswire
HealthPress Release2023-01-25 04:18:00
MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its...

Logo GlobeNewswire
SciencePress Release2023-01-25 02:19:00
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.(Nasdaq: PLRX), a clinical stage biotechnology company focused on...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 14:05:00
Kopin Corporation KOPN, a leading provider of application-specific optical solutions for defense, enterprise, industrial, and consumer products, today...

Logo PR Newswire
HealthPress Release2023-01-25 03:40:00
GERMANTOWN, Md., Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 17:30:00
Did you lose money on investments in Bioventus? If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...

Logo NewsFileCorp
Press Release2023-01-25 17:56:00
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - RUSH URANIUM CORP. (CSE: RSH) (" Rush " or the " Company ") is pleased to announce that it...

Logo PR Newswire
HealthPress Release2023-01-25 23:00:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Gene Therapy Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:30:00
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co.,Ltd. (the Company) (Nasdaq: ANPC), a biotechnology company with operations in...

Logo PR Newswire
HealthPress Release2023-01-25 08:02:00
STOCKHOLM, Jan. 25, 2023 /PRNewswire/ -- Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasdaq Stockholm's...

Logo PR Newswire
HealthPress Release2023-01-25 13:30:00
MARLBOROUGH, Mass., Jan. 25, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 21:20:00
Paragon 28, Inc. FNA ("Paragon"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the...

Logo PR Newswire
HealthPress Release2023-01-26 00:20:00
DUBLIN, Jan. 25, 2023 /CNW/ -- Medtronic plc (NYSE:MDT) recently became aware that TRC Capital Investment Corporation (TRC) has made an unsolicited...

Logo PR Newswire
HealthPress Release2023-01-25 02:15:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The GERD Market by Route of Administration, Type, and Geography - Forecast and Analysis 2023-2027 report has been...

Logo PR Newswire
NYSE American: EU TSX.V: EU www.encoreuranium.com CORPUS CHRISTI, Texas, Jan. 25, 2023 /CNW/ - enCore Energy Corp. (" enCore " or the " Company ") (NYSE...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing...

Logo PR Newswire
HealthPress Release2023-01-24 19:11:00
PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a...

Logo GlobeNewswire
TechnologyPress Release2023-01-24 14:15:00
NEWPORT BEACH, Calif. and LEHI, Utah, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (NASDAQ: VERB) ("VERB" or the "Company"), the leader in...

Logo PR Newswire
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FWBI, GLOP, GOEV, AUPH, and RKLB.

Logo PR Newswire
BOSTON, Jan. 25, 2023 /PRNewswire/ -- Berkshire Hills Bancorp, Inc. (NYSE: BHLB) today announced that its Board of Directors has approved a share repurchase...